Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics Inc (TRDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 439,883
  • Shares Outstanding, K 38,284
  • Annual Sales, $ 25,420 K
  • Annual Income, $ -143,750 K
  • EBIT $ -158 M
  • EBITDA $ -157 M
  • 60-Month Beta -0.12
  • Price/Sales 17.03
  • Price/Cash Flow N/A
  • Price/Book 1.41

Options Overview Details

View History
  • Implied Volatility 383.56% (+50.11%)
  • Historical Volatility 58.57%
  • IV Percentile 71%
  • IV Rank 29.55%
  • IV High 1,251.56% on 09/10/25
  • IV Low 19.44% on 09/09/25
  • Expected Move (DTE 24) 2.04 (18.07%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 10
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 598
  • Open Int (30-Day) 907
  • Expected Range 9.25 to 13.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.06
  • Number of Estimates 4
  • High Estimate -0.97
  • Low Estimate -1.16
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -152.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.05 +2.62%
on 03/06/26
13.65 -16.95%
on 03/11/26
-0.14 (-1.22%)
since 02/24/26
3-Month
9.33 +21.54%
on 01/12/26
13.65 -16.95%
on 03/11/26
+0.76 (+7.18%)
since 12/24/25
52-Week
4.93 +130.02%
on 08/11/25
13.65 -16.95%
on 03/11/26
+0.54 (+5.00%)
since 03/24/25

Most Recent Stories

More News
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – ...

TRDA : 11.41 (-0.70%)
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201  -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2  data by end...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook:...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44 th Annual...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics Reports Third Quarter 2025 Financial Results

-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare...

TRDA : 11.41 (-0.70%)
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- ...

TRDA : 11.41 (-0.70%)

Business Summary

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 12.43
2nd Resistance Point 12.08
1st Resistance Point 11.78
Last Price 11.41
1st Support Level 11.13
2nd Support Level 10.78
3rd Support Level 10.48

See More

52-Week High 13.65
Last Price 11.41
Fibonacci 61.8% 10.32
Fibonacci 50% 9.29
Fibonacci 38.2% 8.26
52-Week Low 4.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.